European Commission Approves Akeega for the Treatment of Patients With BRCA1/2-Mutated Metastatic Hormone-Sensitive Prostate Cancer
March 10, 2026
March 10, 2026
RARITAN, New Jersey, March 10 -- Johnson and Johnson Innovative Medicine issued the following news release on March 9, 2026:
* * *
European Commission approves AKEEGA(R) (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk o . . .
* * *
European Commission approves AKEEGA(R) (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk o . . .